Mullaney D T, John J F
Arch Intern Med. 1983 Sep;143(9):1705-8. doi: 10.1001/archinte.143.9.1705.
Cefotaxime sodium was evaluated in the treatment of ten patients with bacterial meningitis. Seven of the patients were infected with unusual and difficult to eradicate pathogens. Eight of the ten patients had a favorable clinical response and rapid sterilization of their CSF. Trough CSF levels of cefotaxime (range, 5.6 to 44.3 micrograms/mL) and desacetylcefotaxime (3.7 to 44.0 micrograms/mL) were manyfold greater than the minimal bactericidal concentrations of the causative pathogens with the exception of the one Pseudomonas aeruginosa isolate. Trough CSF bactericidal titers ranged from 1:16 to 1:4,096 or more (median, 1:256) in the nine patients with susceptible pathogens. Trough cefotaxime and desacetylcefotaxime levels and bactericidal titers were maintained or actually increased over the course of therapy. Cefotaxime appears to be a promising new agent for the treatment of bacterial meningitis.
对头孢噻肟钠治疗10例细菌性脑膜炎患者进行了评估。其中7例患者感染了不常见且难以根除的病原体。10例患者中有8例临床反应良好，脑脊液迅速除菌。除1株铜绿假单胞菌分离株外，脑脊液中头孢噻肟（范围为5.6至44.3微克/毫升）和去乙酰头孢噻肟（3.7至44.0微克/毫升）的谷浓度比致病病原体的最低杀菌浓度高许多倍。9例病原体敏感的患者脑脊液谷杀菌效价范围为1:16至1:4096或更高（中位数为1:256）。在治疗过程中，头孢噻肟和去乙酰头孢噻肟的谷浓度及杀菌效价得以维持，甚至实际有所增加。头孢噻肟似乎是治疗细菌性脑膜炎的一种有前景的新药。
